The following is a summary of “Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

No writing assistance was utilized in the production of this manuscript. Ocular surface squamous neoplasia is the most common nonpigmented ocular surface lesion. Ocular surface squamous neoplasia ...

The committee identified a potential disparity in results between the squamous and non-squamous non-small cell lung cancer ...

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Fig 1. Summary of systemic therapy for stage I-III anal SSC recommendations. C, conditional; CRT, chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group ...

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...